Comorbidity is an independent predictor of complete remission in elderly patients receiving induction chemotherapy for acute myeloid leukemia

Cancer

Volumn 109, Issue 7, 2007, Pages 1376-1383

  Etienne, Anne ^a   Esterni, Benjamin ^a   Charbonnier, Aude ^a   Mozziconacci, Marie Joëlle ^a   Arnoulet, Christine ^a   Coso, Diane ^a   Puig, Brigitte ^a   Gastaut, Jean Albert ^a   Maraninchi, Dominique ^a   Vey, Norbert ^a  

^a INSTITUT PAOLI CALMETTES   (France)

Author keywords

Acute myeloid leukemia; Comorbidity; Elderly; Induction chemotherapy

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CD34 ANTIGEN; CYTARABINE; DAUNORUBICIN; IDARUBICIN; LOMUSTINE; MELPHALAN; MERCAPTOPURINE; METHOTREXATE; TOPOTECAN;

ACUTE GRANULOCYTIC LEUKEMIA; AGED; ANTIGEN EXPRESSION; ARTICLE; CANCER STAGING; CANCER SURVIVAL; COMORBIDITY; CONTINUOUS INFUSION; DRUG MEGADOSE; FEMALE; HIGH RISK PATIENT; HUMAN; KARYOTYPE; LEUKEMIA CELL; LEUKEMIA REMISSION; LEUKOCYTOSIS; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; RETROSPECTIVE STUDY; SCORING SYSTEM; TREATMENT OUTCOME;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMORBIDITY; CYTOGENETIC ANALYSIS; FEMALE; HUMANS; LEUKEMIA, MYELOID; MALE; PROGNOSIS; REMISSION INDUCTION; RETROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 33947499161     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22537     Document Type: Article

References (38)

1. DeLima M, Ghaddar H, Pierce S, Estey E. Treatment of newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above. Br J Haematol. 1996;93:89-95.
2. Ferrara F, Mirto S, Zagonel V, Pinto A. Acute myeloid leukemia in the elderly: a critical review of therapeutic approaches and appraisal of results of therapy. Leuk Lymphoma. 1998;29(3-4):375-382.
3. Goldstone AH, Burnett AK, Wheatley K, Smith AG, Hutchinson RM, Clark RE. Attempts to improve treatment outcomes in acute myeloid leukemia (AML) in older patients: the results of the United Kingdom Medical Research Council AML11 trial. Blood. 2001;98:1302-1311.
4. Lowenberg B, Zittoun R, Kerkhofs H, et al. On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. J Clin Oncol. 1989;7:1268-1274.
5. Lang K, Earle CC, Foster T, Dixon D, Van Gool R, Menzin J. Trends in the treatment of acute myeloid leukaemia in the elderly. Drugs Aging. 2005;22:943-955.
6. Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006;106:1090-1098.
7. Rowe JM, Neuberg D, Friedenberg W, et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. Blood. 2004;103:479-485.
8. Anderson JE, Kopecky KJ, Willman CL, et al. Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood. 2002;100:3869-3876.
9. Dombret H, Chastang C, Fenaux P, et al. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. AML Cooperative Study Group. N Engl J Med. 1995;332:1678-1683.
10. Buchner T, Berdel WE, Wormann B, et al. Treatment of older patients with AML. Crit Rev Oncol Hematol. 2005;56:247-259.
11. Pinto A, Zagonel V, Ferrara F. Acute myeloid leukemia in the elderly: biology and therapeutic strategies. Crit Rev Oncol Hematol. 2001;39:275-287.
12. Rowe JM. Treatment of acute myelogenous leukemia in older adults. Leukemia. 2000;14:480-487.
13. Gahn B, Haase D, Unterhalt M, et al. De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance. Leukemia. 1996;10:946-951.
14. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood. 2006;107:3481-3485.
15. Leith CP, Kopecky KJ, Chen IM, et al. Frequency and clinical significance of the expression of the multidrug resistance proteins MDR1/P-glycoprotein, MRP1, and LRP in acute myeloid leukemia: a Southwest Oncology Group study. Blood. 1999;94:1086-1099.
16. Lancet JE, Willman CL, Bennett JM. Acute myelogenous leukemia and aging. Clinical interactions. Hematol Oncol Clin North Am. 2000;14:251-267.
17. Estey EH. How I treat older patients with AML. Blood. 2000;96:1670-1673.
18. Chen CC, Yang CF, Yang MH, et al. Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukemia. Ann Oncol. 2005;16:1366-1373.
19. Newschaffer CJ, Bush TL, Penberthy LE, Bellantoni M, Helzlsour K, Diener-West M. Does comorbid disease interact with cancer? An epidemiologic analysis of mortality in a cohort of elderly breast cancer patients. J Gerontol A Biol Sci Med Sci. 1998;53:M372-M378.
20. Singh B, Bhaya M, Stern J, et al. Validation of the Charlson comorbidity index in patients with head and neck cancer: a multi-institutional study. Laryngoscope. 1997;107(11 pt 1): 1469-1475.
21. Birim O, Kappetein AP, Bogers AJ. Charlson comorbidity index as a predictor of long-term outcome after surgery for nonsmall cell lung cancer. Eur J Cardiothorac Surg. 2005; 28:759-762.
22. Hiddemann W, Kern W, Schoch C, et al. Management of acute myeloid leukemia in elderly patients. J Clin Oncol. 1999;17:3569-3576.
23. Sorror ML, Maris MB, Storer B, et al. Comparing morbidity and mortality of HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative and myeloablative conditioning: influence of pretransplantation comorbidities. Blood. 2004;104:961-968.
24. Vey N, Coso D, Bardou VJ, et al. The benefit of induction chemotherapy in patients age ≥75 years. Cancer. 2004; 101:325-331.
25. Dastugue N, Payen C, Lafage-Pochitaloff M, et al. Prognostic significance of karyotype in de novo adult acute myeloid leukemia. The BGMT Group. Leukemia. 1995;9:1491-1498.
26. Charlson ME, Pompei P Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373-383.
27. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer. 2000;36:453-471.
28. Beran M, Estey E, O'Brien S, et al. Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. J Clin Oncol. 1999;17:2819-2830.
29. Montastruc M, Reiffers J, Stoppa AM, et al. Treatment of acute myeloid leukemia in elderly patients: the influence of maintenance therapy (BGM 84 protocol) [in French]. Nouv Rev Fr Hematol. 1990;32:147-152.
30. Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. J Clin Oncol. 2003;21:4642-4649.
31. Kaplan E, Meier P. Nonparametric estimation for incomplete estimation. J Am Stat Assoc. 1958;53:457-462.
32. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer. 1977;35:1-39.
33. Kamikubo K, Murase H, Murayama M, Miura K. Microcomputer-based nonlinear regression analysis of ligand-binding data: application of Akaike's information criterion. Jpn J Pharmacol. 1986;40:342-346.
34. Extermann M, Overcash J, Lyman GH, Parr J, Balducci L. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16:1582-1587.
35. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45:613-619.
36. Extermann M. Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol. 2000;35: 181-200.
37. Diaconescu R, Flowers CR, Storer B, et al. Morbidity and mortality with nonmyeloablative compared with myeloablative conditioning before hematopoietic cell transplantation from HLA-matched related donors. Blood. 2004;104: 1550-1558.
38. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood. 2005; 106:2912-2919.